Nuvectis Pharma Inc (NVCT) - Total Liabilities
Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has total liabilities worth $11.58 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nuvectis Pharma Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how Nuvectis Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Nuvectis Pharma Inc to evaluate short-term liquidity relative to the company's equity base.
Nuvectis Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Nuvectis Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anavex Life Sciences Corp
NASDAQ:AVXL
|
USA | $6.37 Million |
|
Challenger Gold Ltd
AU:CEL
|
Australia | AU$26.26 Million |
|
All Iron Re I Socimi Sa
MC:YAI1
|
Spain | €104.95 Million |
|
Arkade Developers Ltd
NSE:ARKADE
|
India | Rs3.09 Billion |
|
Universal Microelectronics Co Ltd
TW:2413
|
Taiwan | NT$2.15 Billion |
|
Jinpu Landscape Architecture Co.Ltd.
SHE:301098
|
China | CN¥1.91 Billion |
|
GNCO Co. Ltd
KQ:065060
|
Korea | ₩122.63 Billion |
|
Pengana International Equities Ltd
AU:PIA
|
Australia | AU$13.13 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Nuvectis Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nuvectis Pharma Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvectis Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvectis Pharma Inc (2020–2024)
The table below shows the annual total liabilities of Nuvectis Pharma Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.89 Million | +27.35% |
| 2023-12-31 | $6.98 Million | +12.90% |
| 2022-12-31 | $6.19 Million | -64.98% |
| 2021-12-31 | $17.66 Million | +176550.00% |
| 2020-12-31 | $10.00K | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also dev… Read more